RightAnswer Knowledge Solutions Search Results for 672-87-7

RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.

A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.

---

RightAnswer Proprietary Data Sources:

---

All Other Data Sources:

---

ChemID External Links:

---

Other Government Links Searched via RegsKnowledge:

Example Content from MEDITEXT for 672-87-7:

Please note: this is an extract of information from a larger document. Full document and details are available by subscription.

ACUTE EXPOSURE INFORMATION

1. WITH THERAPEUTIC USE
   1. Moderate to severe sedation is the most common adverse effect with metyrosine therapy. Onset occurs within 24 hours of beginning metyrosine therapy with maximal effects occurring after 2 to 3 days of therapy, and then tapering off as therapy is continued. Sedation or fatigue may persist with metyrosine doses of greater than 2000 mg/day.
   2. Other adverse effects that appear to be dose-dependent include extrapyramidal signs (drooling, tremor, and speech difficulty), anxiety, agitation, hallucinations, confusion, diarrhea, and dry mouth. Crystalluria, transient dysuria and hematuria, and hypersensitivity reactions have been reported rarely.

2. WITH POISONING/EXPOSURE
   1. Overdose information is limited. It is anticipated that overdose effects would be an extension of adverse effects occurring during therapeutic use, including sedation, extrapyramidal effects, anxiety, agitation, hallucinations, crystalluria, dysuria and hematuria.

© 2011-2025 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.